HC Q news
See all studies
Late treatment study
Zhong Nanshan (钟南山) (News) (not included in the study count)
Efficacy and safety of ch loroquine for treatment of COVID-19. An open-label, multi-center, non-randomized trial
197 patients. HC Q effective. Viral RNA negative in 95.9% versus 79.6% control. Median time to negative tests 3 days versus 9 days for control. Currently no formal study is available so this is not included in the study count.
Source   Share   Tweet
See all studies
Please send us corrections, updates, or comments.